SEC Filing Summary: Galecto, Inc. (GLTO)
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Galecto, Inc. on June 18, 2025. The company is an emerging growth company incorporated in Delaware, with principal executive offices in Boston, MA, and Copenhagen, Denmark. The filing details the outcomes of three specific proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
All three proposals submitted at the Annual Meeting were approved by the stockholders. The total number of shares entitled to vote was 1,322,359, with 677,821 shares present or represented by proxy.
- Election of Directors: Carl Goldfischer, M.D., and David Shapiro, M.D., were elected as Class II directors to serve until the 2028 Annual Meeting.
- Carl Goldfischer, M.D.: 219,253 votes for; 23,053 votes withheld.
- David Shapiro, M.D.: 226,360 votes for; 15,946 votes withheld.
- There were 435,515 broker non-votes for this proposal.
- Preferred Stock Conversion: Stockholders approved the issuance of common stock upon conversion of Series A non-voting convertible preferred stock issued to Bridge Medicines LLC on October 7, 2024.
- Votes For: 226,407
- Votes Against: 15,099
- Abstentions: 800
- Broker Non-Votes: 435,515
- Ratification of Auditors: Stockholders ratified the selection of EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes For: 660,974
- Votes Against: 16,319
- Abstentions: 528
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard disclosure that the detailed proposals are described in the Definitive Proxy Statement on Schedule 14A filed on April 30, 2025. No unusual items or contingencies were reported in this document.
Key Facts for Investor Verification
- Verify the terms of the Series A non-voting convertible preferred stock issued to Bridge Medicines LLC to understand the dilution impact of the approved conversion.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 30, 2025, for detailed biographies of the newly elected directors and full auditor ratification details.
- Note the significant number of broker non-votes (435,515) on the director election and preferred stock conversion, indicating a large portion of shares held by brokers did not vote on these matters.
- Confirm the company's status as an emerging growth company and its implications for future financial reporting standards.